5323002026-04-012026-06-305323002026-06-305323002026-04-012026-06-30in-capmkt:OtherExpenses1Member5323002026-04-012026-06-30in-capmkt:OtherExpenses2Member5323002026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25323002026-06-30Statement15323002026-04-012026-06-30Statement15323002026-06-30StatementDynamic1I1Statement15323002026-06-30StatementDynamic1I2Statement15323002026-06-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532300WOCKPHARMANOTLISTEDINE049B01025Wockhardt LimitedMain BoardEquity2026-04-012027-03-312026-08-102026-08-04INRCroresQuarterlyFirst quarterSingle segmentPharmaceuticals2026-08-1013:10:002026-08-1015:05:00Not applicabletrue1falseNot Applicable as there is no default on loans and the company has no outstanding debt securities as on 30.06.20262026-04-012026-06-30UnauditedStandalone5610000000330000000594000000010600000005700000008000008500000004300000004100000001549200000487000000010700000000107000000000001070000000000010700000000107000000081000000056.626.61006.626.611)The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The results have been subjected to limited review by the Statutory Auditors of the Company. <br /> <br /> 2)Figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures of the full financial year and the reviewed published figures upto the third quarter of financial year 2025-26. <br /> 3)The Company is exclusively into Pharmaceutical business Segment. <br /> <br /> Other Expenses1550000000Rounding off-800000Items that will not be reclassified to Profit or Loss - credit/(charge) (consisting of re-measurement of net defined benefit liability)800000Rounding Off-8000000000QIP2024-11-11100000000002026-06-30trueCRISIL RATINGS LIMITEDfalseNANILNILRashmi MamturaCompany Secretary and Compliance OfficerMumbai2026-08-10Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company.NO5000000000050000000000Funding in capital expenditure, investment in research and development and incidental expenses.NO2500000000011130000000In view of business exigencies and ongoing project timelines, the period for utilisation of the issue proceeds has <br /> been reviewed and extended by the Board upto financial year 2028 vide its resolution dated 4th May 2026.General Corporate PurposeNO2239700000227790000022779000000During the quarter ended June 30, 2025, net proceeds have been revised from Rs 973.97 crores to Rs 977.79 crores, on account of actual issue expenses being lower than estimated as disclosed in the Offer Document, by Rs 3.82 crores and the same has been adjusted with Object 3: General Corporate Purposes.